Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 1INDUSTRY 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Thoracic 9Other hematologic neoplasm 7Gynecologic 5Gastrointestinal 5Myeloid 4Genitourinary 2CNS 2Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 2Liver Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 228Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Tyrosine Kinase Inhibitors × Gastrointestinal × Clear all
NCT06858956 2025-03-05

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
200 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06682247 2024-11-12

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Sun Yat-sen University

Not yet recruiting
200 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

First Hospital of China Medical University

Active not recruiting
97 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Guangxi Medical University

Phase 2 Completed
56 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Beijing 302 Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡